BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 34437610)

  • 1. COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital.
    Pomej K; Scheiner B; Hartl L; Balcar L; Meischl T; Mandorfer M; Reiberger T; Müller C; Trauner M; Pinter M
    PLoS One; 2021; 16(8):e0256544. PubMed ID: 34437610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic.
    Fründt T; Kuballa L; Lütgehetman M; Nörz D; Arend H; Brehm TT; Schulze Zur Wiesch J; Horvatits T; Horvatits K; Huber S; Wege H; Kluwe J
    PLoS One; 2021; 16(12):e0258450. PubMed ID: 34941875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Improvement in 1-Year Survival Rate of Patients with Hepatocellular Carcinoma BCLC Stage A and B after the Implementation of Comprehensive Management.
    Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S
    J Gastrointest Cancer; 2020 Sep; 51(3):829-835. PubMed ID: 31502104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Tertiary Care Center in North-West Italy.
    Ribaldone DG; Caviglia GP; Gaia S; Rolle E; Risso A; Campion D; Brunocilla PR; Saracco GM; Carucci P
    Curr Oncol; 2022 Feb; 29(3):1422-1429. PubMed ID: 35323319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.
    Weinmann A; Koch S; Niederle IM; Schulze-Bergkamen H; König J; Hoppe-Lotichius M; Hansen T; Pitton MB; Düber C; Otto G; Schuchmann M; Galle PR; Wörns MA
    J Clin Gastroenterol; 2014 Mar; 48(3):279-89. PubMed ID: 24045276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical and oncological outcomes of hepatic resection for BCLC-B hepatocellular carcinoma: a retrospective multicenter analysis among 474 consecutive cases.
    Di Sandro S; Centonze L; Pinotti E; Lauterio A; De Carlis R; Romano F; Gianotti L; De Carlis L;
    Updates Surg; 2019 Jun; 71(2):285-293. PubMed ID: 30941704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hepatocellular carcinoma in a tertiary Romanian center. Deviations from BCLC recommendations and influence on survival rate.
    Radu P; Groza I; Iancu C; Al Hajjar N; Andreica V; Sparchez Z
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):291-7. PubMed ID: 24078986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.
    Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Park MS; Kim EH; Seong J; Lee DY; Han KH
    Liver Int; 2012 Aug; 32(7):1120-7. PubMed ID: 22524688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How COVID-19 has affected emergent visits to a Latin-American trauma department: Experience at a Peruvian national trauma referral center.
    Pintado JF; Gibaja W; Vallejos RA; Rosas W; Guerra-Farfan E; Nuñez JH
    Injury; 2020 Dec; 51(12):2834-2839. PubMed ID: 33162012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic delays are common among patients with hepatocellular carcinoma.
    Patel N; Yopp AC; Singal AG
    J Natl Compr Canc Netw; 2015 May; 13(5):543-9. PubMed ID: 25964640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging.
    Gomaa AI; Al-Khatib A; Abdel-Razek W; Hashim MS; Waked I
    World J Gastroenterol; 2015 May; 21(18):5654-62. PubMed ID: 25987792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
    Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
    Piñero F; Marciano S; Fernández N; Silva J; Anders M; Zerega A; Ridruejo E; Romero G; Ameigeiras B; D'Amico C; Gaite L; Bermúdez C; Reggiardo V; Colombato L; Gadano A; Silva M
    World J Gastroenterol; 2019 Jul; 25(27):3607-3618. PubMed ID: 31367160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regular hospital visits improve the prognosis of hepatocellular carcinoma after initial diagnosis: A single regional community hospital study.
    Watanabe M; Yomokori H; Takahashi Y; Minamino T; Kubo H; Okada T; Yamazaki H; Shibuya A; Koizum W
    Turk J Gastroenterol; 2017 Sep; 28(5):353-360. PubMed ID: 28776496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging.
    Su TH; Liao SH; Hong CM; Liu CJ; Tseng TC; Liu CH; Yang HC; Chen PJ; Chen DS; Chen CL; Adhoute X; Bourlière M; Kao JH
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2179-2186. PubMed ID: 31062879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
    BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.
    Adhoute X; Pénaranda G; Raoul JL; Edeline J; Blanc JF; Pol B; Campanile M; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Castellani P; Le Treut YP; Bronowicki JP; Bourlière M
    World J Gastroenterol; 2017 Apr; 23(14):2545-2555. PubMed ID: 28465639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telephone-Only Visits Preserved Hepatocellular Cancer Screening Rates in Patients with Cirrhosis Early in the COVID-19 Pandemic.
    Rudnick SR; Ugwuegbu J; Soufleris SJ; Bundy R; Dharod A; Russo MW
    Dig Dis Sci; 2023 May; 68(5):1791-1796. PubMed ID: 36562886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.